Mutant p53 : One, No One and One Hundred Thousand
Frontiers in Oncology, 2015 Encoded by the mutated variants of the TP53 tumor suppressor gene, mutant p53 proteins are getting an increased experimental support as active oncoproteins promoting tumor growth and metastasis.
Dawid eWalerych +4 more
doaj +1 more source
The Expression Levels of XLF and Mutant P53 Are Inversely Correlated in Head and Neck Cancer Cells. [PDF]
, 2016 XRCC4-like factor (XLF), also known as Cernunnos, is a protein encoded by the human NHEJ1 gene and an important repair factor for DNA double-strand breaks.
Chen, Wei +8 more
core +2 more sources
Frontiers in Oncology, 2021 Missense p53 mutations (mutp53) occur in approx. 70% of pancreatic ductal adenocarcinomas (PDAC). Typically, mutp53 proteins are aberrantly stabilized by Hsp90/Hsp70/Hsp40 chaperone complexes.
Luisa Klemke +6 more
doaj +1 more source
Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes. [PDF]
, 2017 Functional reactivation of p53 pathway, although arduous, can potentially provide a broad-based strategy for cancer therapy owing to frequent p53 inactivation in human cancer.
Győrffy, Balázs +7 more
core +1 more source
Chromatin dysregulation by mutant p53
Oncotarget, 2016 The TP53 gene, which encodes a DNA sequence-dependent transcriptional regulator, is arguably the most frequently mutated gene in human cancer. Whereas wild-type p53 is restricted to its cognate DNA binding sites, mutant p53 (via mutation in the DNA binding domain) is no longer constrained to specific genomic sites.
Pfister, Neil T., Prives, Carol
openaire +2 more sources
Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes
Nature Communications, 2021 Previous studies report that mutant p53 proteins have gain-of-function activities and cause oncogenic phenotypes. Herein, the authors engineered two isogenic epithelial cell lines to express wild-type or missense mutant p53 or be deficient for p53 ...
Lindsay N. Redman-Rivera +10 more
doaj +1 more source
Cellular and Molecular Gastroenterology and Hepatology, 2022 Background & Aims: TP53 mutations underlie Barrett’s esophagus (BE) progression to dysplasia and cancer. During BE progression, the ubiquitin ligase (E3) RNF128/GRAIL switches expression from isoform 2 (Iso2) to Iso1, stabilizing mutant p53. However,
Paramita Ray +15 more
doaj +1 more source
Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication [PDF]
, 2017 Gain-of-function (GOF) p53 mutations are observed frequently in most intractable human cancers and establish dependency for tumor maintenance and progression.
Beckerman +14 more
core +2 more sources
Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63. [PDF]
PLoS ONE, 2017 Suberoylanilide hydroxamic acid (SAHA) represents one of the new class of anti-cancer drugs. However, multiple lines of clinical evidence indicate that SAHA might be sometimes ineffective on certain solid tumors including pancreatic cancer. In this study,
Takehiro Ogata +8 more
doaj +1 more source
Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53 [PDF]
Nucleic Acids Research, 2007 Tumour-derived p53 mutants are thought to have acquired 'gain-of-function' properties that contribute to oncogenicity. We have tested the hypothesis that p53 mutants suppress p53-target gene expression, leading to enhanced cellular growth. Silencing of mutant p53 expression in several human cell lines was found to lead to the upregulation of wild-type ...
Vikhanskaya, F. +4 more
openaire +2 more sources